Tipifarnib Reduces Extracellular Vesicles and Protects From Heart Failure
Circulation Research · 05.07.2024 · 135 (2) · 280-297
DOI: 10.1161/circresaha.123.324110 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation Research, erschienen am 05.07.2024. Verfasst von Vandana Mallaredy und 13 weiteren Autor:innen. Beteiligte Einrichtung: Aging and Cardiovascular Discovery Center (V.M., Z.C., C.T., C.B., M.T., D.J., A.M., J.I., M.C., C.G., V.N.S.G., R.K.), Lewis Katz School of Medicine…. Hauptthemen laut MEDLINE: Extracellular Vesicles, Heart Failure, Quinolones. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
BACKGROUND: Heart failure (HF) is one of the leading causes of mortality worldwide. Extracellular vesicles, including small extracellular vesicles or exosomes, and their molecular cargo are known to modulate cell-to-cell communication during multiple cardiac diseases. However, the role of systemic extracellular vesicle biogenesis inhibition in HF models is not well documented and remains unclear. METHODS: We investigated the role of circulating exosomes during cardiac dysfunction and remodeling in a mouse transverse aortic constriction (TAC) model of HF. Importantly, we investigate the efficacy of tipifarnib, a recently identified exosome biogenesis inhibitor that targets the critical proteins (Rab27a [Ras associated binding protein 27a], nSMase2 [neutral sphingomyelinase 2], and Alix [ALG-2-interacting protein X]) involved in exosome biogenesis for this mouse model of HF. In this study, 10-week-old male mice underwent TAC surgery were randomly assigned to groups with and without tipifarnib treatment (10 mg/kg 3 times/wk) and monitored for 8 weeks, and a comprehensive assessment was conducted through performed echocardiographic, histological, and biochemical studies. RESULTS: TAC significantly elevated circulating plasma exosomes and markedly increased cardiac left ventricular dysfunction, cardiac hypertrophy, and fibrosis. Furthermore, injection of plasma exosomes from TAC mice induced left ventricular dysfunction and cardiomyocyte hypertrophy in uninjured mice without TAC. On the contrary, treatment of tipifarnib in TAC mice reduced circulating exosomes to baseline and remarkably improved left ventricular functions, hypertrophy, and fibrosis. Tipifarnib treatment also drastically altered the miRNA profile of circulating post-TAC exosomes, including miR 331-5p, which was highly downregulated both in TAC circulating exosomes and in TAC cardiac tissue. Mechanistically, miR 331-5p is crucial for inhibiting the fibroblast-to-myofibroblast transition by targeting HOXC8, a critical regulator of fibrosis. Tipifarnib treatment in TAC mice upregulated the expression of miR 331-5p that acts as a potent repressor for one of the fibrotic mechanisms mediated by HOXC8. CONCLUSIONS: Our study underscores the pathological role of exosomes in HF and fibrosis in response to pressure overload. Tipifarnib-mediated inhibition of exosome biogenesis and cargo sorting may serve as a viable strategy to prevent progressive cardiac remodeling in HF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Aging and Cardiovascular Discovery Center (V.M., Z.C., C.T., C.B., M.T., D.J., A.M., J.I., M.C., C.G., V.N.S.G., R.K.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA.
- Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University School of Medicine, Durham, NC (R.R., W.J.K.).
- Department of Cardiovascular Sciences (V.N.S.G., R.K.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA.
ORCID-Profile: Vandana Mallaredy, Cindy Benedict, Jessica Ibetti, Carolina Gonzalez, Walter J Koch, Raj Kishore
Förderung
- NHLBI NIH HHS
Zitieren
APA
Mallaredy, V., Roy, R., Cheng, Z., Thej, C., Benedict, C., Truongcao, M., Joladarashi, D., Magadum, A., Ibetti, J., Cimini, M., Gonzalez, C., Garikipati, V. N. S., Koch, W. J., & Kishore, R. (2024). Tipifarnib Reduces Extracellular Vesicles and Protects From Heart Failure. Circulation Research, 135(2), 280-297. https://doi.org/10.1161/circresaha.123.324110
Vancouver
Mallaredy V, Roy R, Cheng Z, Thej C, Benedict C, Truongcao M, et al. Tipifarnib Reduces Extracellular Vesicles and Protects From Heart Failure. Circulation Research. 2024;135(2):280-297. doi:10.1161/circresaha.123.324110
BibTeX
@article{Mallaredy2024,
author = {Mallaredy, Vandana and Roy, Rajika and Cheng, Zhongjian and Thej, Charan and Benedict, Cindy and Truongcao, May and Joladarashi, Darukeshwara and Magadum, Ajit and Ibetti, Jessica and Cimini, Maria and Gonzalez, Carolina and Garikipati, Venkata Naga Srikanth and Koch, Walter J and Kishore, Raj},
title = {Tipifarnib Reduces Extracellular Vesicles and Protects From Heart Failure},
journal = {Circulation Research},
year = {2024},
volume = {135},
number = {2},
pages = {280--297},
doi = {10.1161/circresaha.123.324110}
}
EUVIMED